These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2858519)

  • 1. Sulfasalazine and renal tubular function: lack of an effect.
    Koutras A; Daum F; Das KM; Markowitz J; Duffy L; Aiges H; Atkinson M; Fisher SE
    J Pediatr Gastroenterol Nutr; 1985 Feb; 4(1):103-6. PubMed ID: 2858519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease.
    Kreisel W; Wolf LM; Grotz W; Grieshaber M
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):461-8. PubMed ID: 8804875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chronic inflammatory intestinal disease and nephritis].
    Behrens R; Ruder H
    Klin Padiatr; 1992; 204(1):61-4. PubMed ID: 1346814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutical experiments in ulcerative colitis and Crohn's disease.
    Nagy G; Prónay G; Ujszászy L
    Acta Med Hung; 1985; 42(3-4):163-74. PubMed ID: 2869469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulfasalazine-Induced Crystalluria Causing Severe Acute Kidney Injury.
    Durando M; Tiu H; Kim JS
    Am J Kidney Dis; 2017 Dec; 70(6):869-873. PubMed ID: 28669550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: effects of disease activity, acetylator phenotype, and age.
    Clarke DF; George D; Milsap RL; Pogonowska-Wala E; Owerbach J; Lebenthal E; Jusko WJ
    Pediatr Pharmacol (New York); 1982; 2(4):323-33. PubMed ID: 6152489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of drug therapy for inflammatory bowel disease.
    Peppercorn MA
    Compr Ther; 1985 Dec; 11(12):14-9. PubMed ID: 2866866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulfasalazine-induced lupus syndrome in a patient with Crohn's disease.
    Carr-Locke DL
    Am J Gastroenterol; 1982 Sep; 77(9):614-6. PubMed ID: 6126117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity.
    Linares V; Alonso V; Domingo JL
    Expert Opin Drug Saf; 2011 Mar; 10(2):253-63. PubMed ID: 21219240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulfasalazine-induced fulminant hepatitis in pediatric Crohn's disease: report of two cases.
    Besnard M; Debray D; Durand P; Cézard JP; Navarro J
    J Pediatr Gastroenterol Nutr; 1998 Jan; 26(1):119-20. PubMed ID: 9443132
    [No Abstract]   [Full Text] [Related]  

  • 12. Sulfapyridine metabolites in children with inflammatory bowel disease receiving sulfasalazine.
    Goldstein PD; Alpers DH; Keating JP
    J Pediatr; 1979 Oct; 95(4):638-40. PubMed ID: 39125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy of inflammatory bowel disease. Part 1. Sulfasalazine.
    Das KM
    Postgrad Med; 1983 Dec; 74(6):141-8, 150-1. PubMed ID: 6139795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis in children with Crohn's disease.
    Gryboski JD; Spiro HM
    Gastroenterology; 1978 May; 74(5 Pt 1):807-17. PubMed ID: 25221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.
    Chen M; Xia B; Chen B; Guo Q; Li J; Ye M; Hu Z
    Can J Gastroenterol; 2007 Mar; 21(3):155-8. PubMed ID: 17377643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease.
    Nielsen OH
    Scand J Gastroenterol; 1982 Apr; 17(3):389-93. PubMed ID: 6127793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemolytic anemia in patients receiving sulfasalazine.
    Goodacre RL; Ali MA; Vanderlinden B; Hamilton JD; Castelli M; Seaton T
    Digestion; 1978; 17(6):503-8. PubMed ID: 30666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result.
    Ursing B; Alm T; Bárány F; Bergelin I; Ganrot-Norlin K; Hoevels J; Huitfeldt B; Järnerot G; Krause U; Krook A; Lindström B; Nordle O; Rosén A
    Gastroenterology; 1982 Sep; 83(3):550-62. PubMed ID: 6124474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of sulfasalazine in the treatment of inflammatory bowel disease.
    Spector R
    J Iowa Med Soc; 1983 Jun; 73(6):230-4. PubMed ID: 6135735
    [No Abstract]   [Full Text] [Related]  

  • 20. Inflammatory bowel disease and pregnancy.
    Vender RJ; Spiro HM
    J Clin Gastroenterol; 1982 Jun; 4(3):231-49. PubMed ID: 6124570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.